PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, today announces the completion of enrolment of the fourth cohort of patients in its PDC-LUNG-101 phase I/II clinical trial (NCT03970746) with PDC*lung01, the company’s therapeutic cancer vaccine candidate for Non-Small Cell Lung Cancer (NSCLC). This cohort, B2, was designed to assess PDC*lung01 at ‘high dose’, added to pembrolizumab in monotherapy in a first-line stage IV setting. It includes 45 patients.

PDC*line Pharma was granted with the “Best Startup” award by the MATWIN Board in 2017 !

Full press release: